Skip to main content

Table 1 (abstract P97). Patient and physician assessment of clinical CAPS disease activity and laboratory markers over time

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

Baseline

12 months

30 months

 

Total cohort

NOMID/ CINCA

Total cohort

NOMID/ CINCA

Total cohort

NOMID/ CINCA

Number of patients, N

91

14

67

8

28

4

Number (%) of patients in disease remission (physician assessment)

61 (68.5)

11 (78.6)

42 (66.7)

4 (66.7)

19 (67.9)

4 (100.0)

Physician Global Assessment, percentage of absent/mild-moderate/severe rating, %

40 / 53 / 2

57 / 36 / 0

33 / 60 / 2

33 / 50 / 0

61 / 39 / 0

75 / 25 / 0

Patient assessment of current disease activity; 0–10, median (min; max)

2.0 (0; 7)

1.0 (0; 6)

1.0 (0; 7)

1.0 (0; 5)

0.0 (0; 7)

0.0 (0; 4)

Patient assessment of current fatigue; 0–10, median (min; max)

3.0 (0; 9)

2.0 (0; 6)

3.0 (0; 8)

2.0 (0; 8)

1.0 (0; 8)

4.0 (0; 5)

Number (%) of patients without impairment of social life by the disease

32 (52.5)

4 (50.0)

31 (62.0)

3 (42.9)

11 (47.8)

1 (33.3)

CRP/SAA, median (mg/dl)

0.1/0.3

0.2/0.4

0.1/0.5

0.5/0.9

0.0/0.3

0.2/0.1

  1. CRP c-reactive protein, SAA serum amyloid A